TOP > 外国特許検索 > NANOREACTOR USING POLYION COMPLEX POLYMERSOMES, AND METHOD FOR PRODUCING SAME

NANOREACTOR USING POLYION COMPLEX POLYMERSOMES, AND METHOD FOR PRODUCING SAME

外国特許コード F170008922
整理番号 (S2015-1455-N0)
掲載日 2017年1月19日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP063684
国際公開番号 WO 2016178431
国際出願日 平成28年5月6日(2016.5.6)
国際公開日 平成28年11月10日(2016.11.10)
優先権データ
  • 特願2015-095278 (2015.5.7) JP
発明の名称 (英語) NANOREACTOR USING POLYION COMPLEX POLYMERSOMES, AND METHOD FOR PRODUCING SAME
発明の概要(英語) The present invention provides a nanoreactor (nano-sized reaction field) using polyion complex polymersomes, and a method for producing the nanoreactor. The present invention provides polyion complex polymersomes including, for example, an enzyme, wherein a substrate for the enzyme is a substance which passes through the membrane of the polyion complex polymersomes.
特許請求の範囲(英語) [claim1]
1. Being poly- ion complex type [porimasomu] which contains the enzyme,
The enzyme is the enzyme which designates the substance which transmits the membrane of poly- ion complex type [porimasomu] as the substrate, poly- ion complex type [porimasomu].
[claim2]
2. The molecular weight of the enzyme, is above 5kDa, in claim 1 poly- ion complex type [porimasomu] of statement.
[claim3]
3. The molecular weight of the substrate of the enzyme, is below 1kDa, in claim 1 or 2 poly- ion complex type [porimasomu] of statement.
[claim4]
4. The enzyme, is the globular protein, either of the claim 1-3 in one section poly- ion complex type [porimasomu] of statement.
[claim5]
5. The enzyme, is the enzyme which is selected from [L]-asuparaginaze, [urikaze], ***.alpha.-garakutoshidaze and ***.alpha.-gurukoshidaze, in claim 1 poly- ion complex type [porimasomu] of statement.
[claim6]
6. Poly- ion complex type [porimasomu],
The polymer which includes the amino acid which possesses the COOH basis in the side chain as the monomer unit (A) and,
NH [2] the polymer which includes the amino acid which possesses the basis in the side chain as the monomer unit (B)
It is poly- ion complex type [porimasomu], either of the claim 1-5 in one section poly- ion complex type [porimasomu] of statement.
[claim7]
7. 50% or more of the COOH basis which exists in the polymer (A) builds a bridge the polymer (B) NH [2] the basis,
The [te] it is, in claim 6 poly- ion complex type [porimasomu] of statement.
[claim8]
8. When it measured under 37.deg.C condition the 10mM phosphoric acid buff solution (pH7.4) in, cumulative discharge ratio of the enzyme which is contained (%) the aforementioned aqueous solution and after the contacting on 7th day is 20% or less, either of the claim 1-7 in one section poly- ion complex type [porimasomu] of statement.
[claim9]
9. When it measured under 37.deg.C condition the 10mM phosphoric acid buff solution (pH7.4) in, discharge velocity factor k of the direct condition polyethylene glycol of Kazuhei equal molecular weight 2kDa the 5x10 (- 3) is below, in claim 7 poly- ion complex type [porimasomu] of statement.
[claim10]
10. Either of the claim 1-9 being poly- ion complex type [porimasomu] of statement in one section, the enzyme which is contained, designates the blood plasma component as the substrate, poly- ion complex type [porimasomu].
[claim11]
11. Including poly- ion complex type [porimasomu] of claim, 10 it becomes, the medicine composition.
[claim12]
12. The medicine composition, enzyme deficiency or was the medicine composition in order to prescribe to the patient who has contracted a disease in the disease which makes abnormality originating, the enzyme, deficiency did in the said object, or it is the enzyme which possesses abnormality, in claim 11 the medicine composition of statement.
[claim13]
13. The enzyme, is the enzyme which is selected from [L]-asuparaginaze, [urikaze], ***.alpha.-garakutoshidaze, and ***.alpha.-gurukoshidaze, in claim 11 or 12 the medicine composition of statement.
[claim14]
14. The enzyme, is the enzyme which disassembles the nutrient which is necessary for the growth of the neoplasm or the microbe, in claim 11 the medicine composition of statement.
[claim15]
15. In claim 13 in order to deal with the asparagine required characteristic tumor the medicine composition of statement.
[claim16]
16. The asparagine required characteristic tumor, the revelation quantity of the asparagine production enzyme, it is the tumor which is 80% or less vis-a-vis the revelation quantity of the said enzyme in the normal cell, in 15 the medicine composition of statement.
[claim17]
17. The asparagine required characteristic tumor, the acutely lymph characteristic leukemia, the T cell malignant lymph swelling, is selected from the group which consists of the NK cellularity leukemia and the acutely marrow characteristic leukemia, in claim 15 or 16 the medicine composition of statement.
[claim18]
18. The enzyme, is ***.alpha.-garakutoshidaze, in claim 11 in order to use for dealing with the disease which makes the abnormality of ***.alpha.-garakutoshidaze causing or 12 the medicine composition of statement.
[claim19]
19. The enzyme, is [urikaze], in claim 11 in order to use for dealing with the disease which makes the high urine acidosis or the high urine acidosis causing or 12 the medicine composition of statement.
[claim20]
20. The enzyme, is ***.alpha.-gurukoshidaze, in claim 11 in order to use for dealing with the disease which makes the abnormality of ***.alpha.-gurukoshidaze causing or 12 the medicine composition of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • UNIVERSITY OF TOKYO
  • 発明者(英語)
  • KATAOKA KAZUNORI
  • ANRAKU YASUTAKA
  • SUEYOSHI DAIKI
国際特許分類(IPC)
指定国 (WO2016178431)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close